Next-generation therapies for adrenocortical carcinoma.

Almost one decade ago, etoposide, doxorubicin, cisplatin and mitotane (EDP-M) has been established as first-line systemic therapy of metastatic adrenocortical carcinoma (ACC). Although heterogeneous, the prognosis of advanced stage ACC is still poor and novel treatments are urgently needed. This article provides a short summary of current systemic ACC treatment and provides a comprehensive overview of new therapeutic approaches that have been investigated in the past years, including drugs targeting the IGF pathway, tyrosine kinase inhibitors, radionuclide treatment, and immunotherapy. The results of most of these trials were disappointing and we will discuss possible reasons why these drugs failed (e.g. drug interactions with mitotane, disease heterogeneity with exceptional responses in very few patients, and resistance mechanisms to immunotherapy). We then will present potential new drug targets that have emerged from many molecular studies (e.g. wnt/β-catenin, cyclin-dependent kinases, PARP1) that may be the foundation of next-generation therapies of ACC. Copyright © 2020 Elsevier Ltd. All rights reserved.

Citation

Barbara Altieri, Cristina L Ronchi, Matthias Kroiss, Martin Fassnacht. Next-generation therapies for adrenocortical carcinoma. Best practice & research. Clinical endocrinology & metabolism. 2020 May;34(3):101434

Mesh Tags

Substances

PMID: 32622829

search → result